Oncology · Clinically Validated Solid-Tumour NGS Panel · DNA + RNA

OncoFocus52 Every variant class, one small sample.

A targeted NGS assay that profiles 52 solid-tumour genes for hotspot SNVs, indels, copy-number gains and gene fusions from DNA and RNA in a single workflow — from as little as 10 ng of each, including FFPE fine-needle aspirates and core-needle biopsies. Built on the Oncomine Focus Assay (Thermo Fisher Scientific) and run on the Ion GeneStudio S5.

52
solid-tumour genes
4
variant classes: SNV · indel · CNV · fusion
10 ng
DNA + 10 ng RNA input
FFPE
FNA and core-needle compatible

OncoFocus52 at Nucleome Informatics

OncoFocus52 reads 52 genes that drive solid tumours or are targeted by on-market oncology drugs and published evidence, with content driven by the Oncomine Knowledgebase. DNA and RNA are analysed together, so one small biopsy answers questions that would otherwise need several separate tests.

Who should order this test

  • Oncologists and pathologists who need broad solid-tumour biomarker profiling from limited samples — FFPE blocks, fine-needle aspirates and core-needle biopsies
  • Cancer researchers and translational programmes that need sequence variants, copy-number gains and fusions from one assay
  • Clinical research teams where sample conservation matters as much as breadth

What you receive

  • Variant calls for all four classes: SNVs, indels, copy-number gains and gene fusions
  • Evidence-linked annotation of each variant to drug labels and published evidence (Oncomine Reporter)
  • A structured report with coverage, QC metrics and per-variant evidence
  • Raw data and variant-call files for your records
  • A review call with our scientific team to discuss the findings in context

Why one assay for all variant classes?

  • Sample conservation: DNA and RNA from the same specimen are analysed in one workflow — no repeat extraction or re-biopsy for each biomarker.
  • Fusions included: RNA-based detection covers ALK, ROS1, RET and NTRK1/2/3 fusions, which DNA-only hotspot panels can miss.
  • Copy-number gains: amplifications of genes such as ERBB2, MET, EGFR and FGFR1 are called from the same DNA library.
  • Speed: a 3-day tissue-to-report platform workflow on Ion Torrent sequencing, with optional Ion Chef automation.
Figure 1 What each testing approach can detect. schematic
Single-gene testsDNA-only hotspot panelOncoFocus52 Hotspot SNVs and indels Copy-number gains (amplifications) Gene fusions (RNA) Many genes from one 10 ng input CoveredOne gene or test at a time / partialNot covered
Figure 1 | Single-gene tests (PCR, FISH, IHC) answer one question per test and consume tissue each time; DNA-only hotspot panels miss RNA fusions. OncoFocus52 reads all four classes from one input. (Illustrative schematic, not sample data.)

52 genes, grouped by variant class

Content of the Oncomine Focus Assay as published by Thermo Fisher Scientific. Some genes appear in more than one group; there are 52 unique genes in total.

Hotspot genes SNVs and indels · 35 genes · DNA

AKT1ALKARBRAFCDK4CTNNB1DDR2EGFRERBB2ERBB3ERBB4ESR1FGFR2FGFR3GNA11GNAQHRASIDH1IDH2JAK1JAK2JAK3KITKRASMAP2K1MAP2K2METMTORNRASPDGFRAPIK3CARAF1RETROS1SMO

Copy-number genes amplifications · 20 genes · DNA

AKT1ALKARBRAFCCND1CDK4CDK6EGFRERBB2FGFR1FGFR2FGFR3FGFR4KITKRASMETMYCMYCNPDGFRAPIK3CA

Fusion genes RNA · 23 genes

ABL1AKT3ALKAXLBRAFEGFRERBB2ERGETV1ETV4ETV5FGFR1FGFR2FGFR3METNTRK1NTRK2NTRK3PDGFRAPPARGRAF1RETROS1

The DNA panel uses 269 amplicons; the RNA panel targets 271 known fusion isoforms plus expression-control amplicons. Copy-number analysis is designed for gains (amplifications) of these oncogenes, not for gene deletions.

What to send, what you receive

Reference inputs from the assay user guide. Final requirements are confirmed at intake.

Sample typeWhat to sendNotes
FFPE tissueFFPE block, or unstained sections/scrolls with a matching H&E slidePathologist-marked tumour area preferred; ship at room temperature
Fine-needle aspirate / core-needle biopsyFFPE cell block or coreValidated for low-volume biopsies
Fresh-frozen tissueFrozen tissueShip on dry ice; avoid freeze–thaw
Extracted nucleic acids10 ng DNA and 10 ng DNase-treated RNA per reactionQuantified by Qubit or TaqMan RNase P (DNA) and Qubit RNA HS (RNA); spectrophotometry is not recommended

Tumour content matters: variants are reported down to about 5% allele frequency, so low-tumour samples reduce sensitivity. RNA quality drives fusion detection — send the freshest material available when fusions are the priority.

Deliverables

  • Report of detected SNVs, indels, copy-number gains and fusions, with evidence-linked annotation (Oncomine Reporter)
  • Coverage and QC metrics per sample, including RNA expression controls and no-template controls
  • Raw data and variant-call files (BAM, VCF and fusion tables)
  • A review call with our scientific team

From tissue to report

The documented platform workflow takes about 3 days from extracted sample to report. Overall turnaround, including shipping and review, is agreed per project.

Figure 2 OncoFocus52 workflow. schematic
FFPE / FNA / coresample intake DNA + RNA extraction(10 ng each) RNA → cDNA; AmpliSeqtarget amplification Barcoded libraries(manual or Ion Chef) Templating onIon Chef Ion GeneStudio S5sequencing Torrent Suite QC +Ion Reporter calling Oncomine Reporterreport + review call
Figure 2 | OncoFocus52 workflow. Paired DNA and RNA libraries from up to seven samples, plus no-template controls, are sequenced together on one Ion 520 chip. (Illustrative schematic.)

Documented sensitivity and specificity

Thermo Fisher's analytical performance summary for the Oncomine Focus Assay, using clinical research samples sequenced on the Ion GeneStudio S5 System.

Variant classSensitivityPPV (positive predictive value)Reproducibility
SNVs98.77%99.63%99.6%
Indels100%100%100%
CNVs (gains)96.42%100%96.42%
Gene fusions100%100%100%
Overall98.70%99.67%99.01%

Source: Thermo Fisher Scientific, Oncomine Focus Assay analytical performance summary. Default reporting thresholds in the Ion Reporter workflow: hotspot variants at allele frequency ≥5% with ≥10 supporting reads; copy-number gains where the lower 5% confidence bound of fold change is ≥2.

From first principles to study design

New here? Start with Foundations. Planning a study or reading a report? Jump to Practitioner or Expert.

Six ideas that explain what this test is and why it matters.

LEVEL 1

What is a targeted NGS panel?

Instead of sequencing the whole genome, a panel reads a selected set of genes deeply and affordably — here, 52 genes that drive solid tumours or predict therapy response.

LEVEL 1

SNVs, indels, CNVs and fusions

SNVs are single-letter changes; indels are small insertions or deletions; CNVs here are gene amplifications; fusions are two genes joined by a chromosome rearrangement.

LEVEL 1

Why DNA and RNA?

DNA shows sequence changes and copy number; RNA shows fusions directly as fused transcripts. Using both from one sample gives the full picture.

LEVEL 1

What is FFPE?

Formalin-fixed, paraffin-embedded tissue is how pathology labs store biopsies. Fixation damages DNA and RNA, so this short-amplicon chemistry is built for degraded material.

LEVEL 1

What will I get?

A report of detected variants linked to therapies and evidence, with coverage and QC metrics, the raw data, and a review call with our team.

LEVEL 1

Who is this test for?

Oncologists, pathologists and cancer researchers who need broad biomarker profiling from small or archived samples.

How each step works and what to check in the report.

LEVEL 2

Library preparation

10 ng DNA is amplified directly; 10 ng RNA is first reverse-transcribed to cDNA. Amplification cycles are increased for FFPE material to compensate for damage.

LEVEL 2

Templating and sequencing

Barcoded libraries are pooled, templated on the Ion Chef and sequenced on an Ion 520 chip on the Ion GeneStudio S5.

LEVEL 2

Variant calling

Torrent Suite runs QC and alignment; Ion Reporter calls hotspot SNVs/indels, copy-number gains and fusions from the DNA and RNA data.

LEVEL 2

Evidence-linked reporting

Oncomine Reporter links each biomarker to drug labels, guidelines and published evidence, and our team reviews the findings with you.

LEVEL 2

Quality metrics you will see

Mapped reads, amplicon coverage and uniformity, RNA expression-control reads, fusion-supporting read counts, and clean no-template controls.

LEVEL 2

Samples in practice

FFPE blocks or sections, FNA cell blocks and core biopsies all work; tumour-rich areas marked on an H&E slide give the best sensitivity.

The decisions that determine how to read a positive — or a negative — result.

LEVEL 3

Performance by variant class

Overall sensitivity is 98.70% and PPV 99.67%; CNV sensitivity (96.42%) is the lowest class, so treat a CNV-negative result with the most caution.

LEVEL 3

Tumour content and the 5% threshold

Heterozygous variants in a sample with 10% tumour cells appear at about 5% allele frequency — the reporting floor. Enrich tumour area before extraction where possible.

LEVEL 3

Fusions depend on RNA

The RNA panel detects 271 known fusion isoforms. Novel partners or breakpoints outside the design are not detected, and badly degraded RNA lowers sensitivity.

LEVEL 3

Copy-number scope

CNV calling targets amplifications of 20 oncogenes. Deletions of tumour suppressors (e.g. CDKN2A, PTEN) are outside the assay design.

LEVEL 3

Panel vs broad profiling

OncoFocus52 trades breadth for speed, depth and sample economy. For TMB, MSI, tumour suppressors or discovery, choose OncoTotal500 or genome-wide approaches.

LEVEL 3

Clinical validation

Thermo Fisher labels the Oncomine Focus Assay kit For Research Use Only. Nucleome has validated OncoFocus52 in its own laboratory for clinical use.

AmpliSeq
amplicon-based targeted enrichment chemistry suited to low-input, degraded samples.
FFPE
formalin-fixed paraffin-embedded tissue; standard pathology storage.
FNA
fine-needle aspirate; a minimally invasive biopsy.
Allele frequency
the percentage of reads carrying a variant; diluted by normal cells in the sample.
Ion Chef
automated instrument for library templating and chip loading.
PPV
positive predictive value; the share of reported calls that are true.

Built for small, difficult samples

The platform, chemistry and software behind the test.

Ion AmpliSeq chemistry

Short amplicons give robust results from low-input and FFPE-damaged DNA and RNA.

52-gene multi-class content

Hotspot, copy-number and fusion groups spanning EGFR, KRAS, BRAF, ERBB2, MET, ALK, ROS1, RET and NTRK1/2/3.

Ion GeneStudio S5

Semiconductor sequencing; the S5 chip range spans 2M–130M reads per run, and an Ion 520 chip handles up to seven paired DNA/RNA samples.

Ion Chef automation

Hands-free templating and chip loading for reproducible, low-touch processing.

Integrated informatics

Torrent Suite for run QC, Ion Reporter for variant and fusion calling, Oncomine Reporter for evidence-linked reports.

Connected to our bioinformatics

Further interpretation, tiering and multi-omics context through our Bioinformatics team.

What this test does and does not cover

Scope note. OncoFocus52 detects hotspot SNVs and indels, copy-number gains and known fusions in 52 genes. It does not detect gene deletions, mutations outside the targeted hotspots, novel fusion partners, tumour mutational burden, microsatellite instability or germline predisposition — for these, see OncoTotal500 or genome-wide approaches. Sensitivity depends on tumour content and, for fusions, RNA quality. OncoFocus52 is validated in Nucleome's laboratory for clinical use; the underlying Oncomine Focus Assay kit is labelled For Research Use Only by Thermo Fisher Scientific, which is why we carried out our own validation. Results should be interpreted alongside the full clinical and pathological picture. Turnaround times and pricing are defined per project.

Service highlights

What you can expect from our team in Hyderabad.

All four classes, one run

SNVs, indels, copy-number gains and fusions from DNA and RNA — no repeat testing.

10 ng input, FFPE-ready

Works from fine-needle aspirates, core biopsies and archived blocks.

Evidence-linked reports

Each biomarker linked to drug labels and published evidence.

Documented performance

98.70% sensitivity and 99.67% PPV overall in Thermo Fisher's analytical summary.

Fast by design

A 3-day platform workflow with optional Ion Chef automation.

A path to broader testing

Step up to OncoTotal500 or genome-wide sequencing when the question needs more breadth.

Frequently asked, in plain language

From the basics to the finer points of interpretation.

basicWhat is OncoFocus52?
A targeted NGS assay that profiles 52 solid-tumour genes for hotspot SNVs, indels, copy-number gains and gene fusions from DNA and RNA in a single workflow.
basicWhat samples does it accept?
FFPE tissue (blocks or sections), FFPE fine-needle aspirates and core-needle biopsies, fresh-frozen tissue, or extracted nucleic acids. The reference input is 10 ng DNA and 10 ng RNA.
basicWhich genes are covered?
52 unique genes including EGFR, KRAS, BRAF, ERBB2, MET, ALK, ROS1, RET and NTRK1/2/3. The full list, grouped by variant class, is on this page.
intermediateWhy does the assay use both DNA and RNA?
DNA shows sequence changes and copy number; RNA shows fusions directly as fused transcripts, which DNA-only tests can miss. Both come from one sample.
intermediateWhat will the report contain?
Detected variants with evidence-linked annotation, coverage and QC metrics, and raw data files, followed by a review call with our scientific team.
intermediateIs OncoFocus52 validated for clinical use?
Yes. Nucleome has validated OncoFocus52 in its own laboratory for clinical use. The underlying Oncomine Focus Assay kit is labelled For Research Use Only by Thermo Fisher, which is why we performed our own validation.
intermediateDoes it detect gene deletions?
No. Copy-number analysis is designed for amplifications of 20 oncogenes such as ERBB2, MET, EGFR and FGFR1. Tumour-suppressor deletions need a broader panel such as OncoTotal500.
advancedHow sensitive is the assay?
Thermo Fisher reports 98.70% overall sensitivity and 99.67% PPV. CNV sensitivity (96.42%) is the lowest class. Variants are reported down to about 5% allele frequency, so tumour content matters.
advancedCan it detect NTRK fusions?
Yes — NTRK1, NTRK2 and NTRK3 are among the 23 fusion genes, alongside ALK, ROS1, RET and 17 others. The RNA panel targets 271 known fusion isoforms; novel partners are not detected.
advancedHow does it compare with broader profiling?
OncoFocus52 is fast and sample-sparing for the most actionable solid-tumour genes. For TMB, MSI, tumour suppressors or discovery, choose OncoTotal500 or genome-wide sequencing — we can advise at design.
advancedHow many samples run together?
Up to seven paired DNA/RNA samples plus no-template controls on one Ion 520 chip, per the assay user guide. Larger studies are batched across runs.

Key literature & resources

Assay content, workflow and performance are documented by Thermo Fisher Scientific.

  1. Thermo Fisher Scientific. Oncomine Focus Assay — product information, gene list, workflow and analytical performance summary. thermofisher.com
  2. Thermo Fisher Scientific. Oncomine Focus Assay User Guide (Pub. No. MAN0015819, Rev. D.0, 18 September 2023; Cat. Nos. A29230, A35957, A42008). PDF
  3. Thermo Fisher Scientific. Ion GeneStudio S5 Series, Ion Chef System, Torrent Suite, Ion Reporter and Oncomine Reporter product documentation.